Robert F. Kennedy Jr.

so that people who get the money tend to be people who have been approved by the industry through, you know, a variety of, of levers. And they are part of an old boys network that knows what they can say and what they can't say and what they can research and what they can't. And they're not going to research anything that with the results may diminish corporate profits.

The other thing is there's no replication. So there's a huge incentive to cheat on your science. So if you, if you go to your funder with a hypothesis and say, this is what I believe, here's how I'm going to prove it. And it's going to be an important decision. And then the science does not confirm that hypothesis. That's science.

The other thing is there's no replication. So there's a huge incentive to cheat on your science. So if you, if you go to your funder with a hypothesis and say, this is what I believe, here's how I'm going to prove it. And it's going to be an important decision. And then the science does not confirm that hypothesis. That's science.

The other thing is there's no replication. So there's a huge incentive to cheat on your science. So if you, if you go to your funder with a hypothesis and say, this is what I believe, here's how I'm going to prove it. And it's going to be an important decision. And then the science does not confirm that hypothesis. That's science.

When the hypothesis doesn't always work in your favor, when it's a null hypothesis, that science and ought to be published and it doesn't get published.

When the hypothesis doesn't always work in your favor, when it's a null hypothesis, that science and ought to be published and it doesn't get published.

When the hypothesis doesn't always work in your favor, when it's a null hypothesis, that science and ought to be published and it doesn't get published.

But the private funding is coming from industry. So they cheat. I mean, we call those guys by constitutes because they, you know, they know what the outcome is and they write the outcome before they write the study. In many cases, that also happens in the public sphere. And so what we're going to do, and it happens because they know there's going to be no replication.

But the private funding is coming from industry. So they cheat. I mean, we call those guys by constitutes because they, you know, they know what the outcome is and they write the outcome before they write the study. In many cases, that also happens in the public sphere. And so what we're going to do, and it happens because they know there's going to be no replication.

But the private funding is coming from industry. So they cheat. I mean, we call those guys by constitutes because they, you know, they know what the outcome is and they write the outcome before they write the study. In many cases, that also happens in the public sphere. And so what we're going to do, and it happens because they know there's going to be no replication.

A lot of times the data sets are private. You know, you buy UnitedHealthcare data sets. They're only selling to you, so you can't publish them. And so there's no replication. And if you know there's going to be no effort to replicating your study, you have a huge incentive to change.

A lot of times the data sets are private. You know, you buy UnitedHealthcare data sets. They're only selling to you, so you can't publish them. And so there's no replication. And if you know there's going to be no effort to replicating your study, you have a huge incentive to change.

A lot of times the data sets are private. You know, you buy UnitedHealthcare data sets. They're only selling to you, so you can't publish them. And so there's no replication. And if you know there's going to be no effort to replicating your study, you have a huge incentive to change.

And so what we're going to do is we're going to devote probably 20% of NIH's budget to replication. Every study has to be replicated. We're going to publish the peer review for the first time. We're probably going to stop publishing in the Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt.

And so what we're going to do is we're going to devote probably 20% of NIH's budget to replication. Every study has to be replicated. We're going to publish the peer review for the first time. We're probably going to stop publishing in the Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt.

And so what we're going to do is we're going to devote probably 20% of NIH's budget to replication. Every study has to be replicated. We're going to publish the peer review for the first time. We're probably going to stop publishing in the Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt.

And even the heads of those journals, like Marsh Angle, who for 20 years was head of the New England Journal of Medicine, says that we no longer are a science journal. We are a vessel for pharmaceutical propaganda. No kidding. Because they control the journals. They buy the preprints, right? If you want to publish in a journal, you have to pay $10,000 to get the study published.

And even the heads of those journals, like Marsh Angle, who for 20 years was head of the New England Journal of Medicine, says that we no longer are a science journal. We are a vessel for pharmaceutical propaganda. No kidding. Because they control the journals. They buy the preprints, right? If you want to publish in a journal, you have to pay $10,000 to get the study published.

And even the heads of those journals, like Marsh Angle, who for 20 years was head of the New England Journal of Medicine, says that we no longer are a science journal. We are a vessel for pharmaceutical propaganda. No kidding. Because they control the journals. They buy the preprints, right? If you want to publish in a journal, you have to pay $10,000 to get the study published.

So the pharmaceutical company concocts a study that shows the outcome that they want, that statins work or that SSRIs work. And then they'll publish that. They pay to get that published. And they order reprints from the journal. The reprints, as you know, RA, it's a five or six page document that has the logo of the journal on it.